Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.
We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia. 229 patients were genotyped by real-time PCR hybridization probe melting curve technique for CYP2C19*2, CYP2D6*3, *4, and *6, respectively. The gene deletion CYP2D6*5 was analyzed by a long PCR method. Detailed clinical information was obtained from 53 subjects. Patients genotyped homozygous or heterozygous for those CYP2D6 and CYP2C19 poor metabolizer alleles were treated for a longer time in hospital (median 57.5 vs. 40.0 days). Psychiatric patients might benefit from CYP genotyping, the duration of stay as inpatient might be reduced by a priori selection of the appropriate drug for the individual patient.
Kropp
Stefan
S
Department of Clinical Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
Lichtinghagen
Ralf
R
Winterstein
Kathrin
K
Schlimme
Jann
J
Schneider
Udo
U
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism; D005838:Genotype; D006778:Hospitals, Psychiatric; D006801:Humans; D007902:Length of Stay; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010865:Pilot Projects; D011110:Polymorphism, Genetic; D011619:Psychotropic Drugs / Q000378:metabolism / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D044465:White People
D011619:Psychotropic Drugs; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6